NAD+ (Buffered) — Research Overview
Chemical Name: Nicotinamide Adenine Dinucleotide (oxidized form) Also Known As: NAD+, NAD, beta-nicotinamide adenine dinucleotide, DPN (diphosphopyridine nucleotide — historical name) Structure: Dinucleotide consisting of two nucleotides joined by a phosphate linkage — adenosine monophosphate (AMP) connected to nicotinamide mononucleotide (NMN) through a 3′,5′ phosphoanhydride bond. The nicotinamide ring is the site of the pyridinium/dihydropyridine redox reaction. The “Buffered” Formulation: The buffered designation refers to a pH-adjusted preparation designed to reduce injection site discomfort and improve tolerability during intravenous or intramuscular administration. NAD+ in solution is acidic; pH buffering to approximately physiological range significantly reduces the burning or stinging commonly associated with infusion of unbuffered NAD+ solutions. Molecular Weight: 663.43 daltons Redox Partner: NAD+ is the oxidized form; NADH is its reduced partner. Together they constitute the NAD+/NADH redox couple, one of the most important electron-carrier pairs in biochemistry. Historical Note: NAD+ was discovered over 100 years ago by Sir Arthur Harden, who identified it as a low molecular weight substance in yeast extract that stimulated fermentation. The structure was subsequently elucidated over several decades. For most of the 20th century NAD+ appeared in biochemistry texts primarily as a coenzyme for oxidation-reduction reactions. The discovery of sirtuins, PARPs, and CD38 as NAD+-consuming signaling enzymes in the late 20th century fundamentally expanded the biological significance of NAD+ from a metabolic electron carrier to a centrally important signaling molecule. Related Molecules: NAD+ is closely related to NADH (reduced form), NADP+ (phosphorylated derivative involved in anabolic reactions and antioxidant defense), and NADPH (reduced NADP+). NAD+ precursors including nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinamide (NAM), and niacin (nicotinic acid/NA) are all studied as strategies to raise intracellular NAD+ levels. Category: Essential endogenous redox coenzyme / NAD+-consuming signaling substrate / sirtuin cofactor / PARP substrate / mitochondrial electron transport component / aging and longevity research tool
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption outside of any applicable approved indications. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is NAD+?
Nicotinamide adenine dinucleotide in its oxidized form (NAD+) is one of the most fundamental molecules in cellular biochemistry — a coenzyme and signaling substrate present in virtually every living cell that participates in hundreds of enzymatic reactions essential for life. Discovered more than a century ago and found in every textbook of biochemistry as a metabolic electron carrier, NAD+ has in recent decades been revealed to be far more than a passive redox shuttle. It is now understood as a critical signaling currency connecting cellular energy status to gene expression, DNA repair, immune function, circadian rhythm, and the biology of aging.
The central biological significance of NAD+ in the context of aging research derives from two converging observations: NAD+ levels decline substantially and consistently with age across multiple tissues in humans and model organisms, and this decline is mechanistically linked to the functional deterioration that characterizes aging at the cellular level. Published research has documented NAD+ declines in human blood, skin, liver, muscle, and brain as a function of age. The magnitude of decline is substantial — in some tissue studies, NAD+ levels in older adults are approximately 50% of levels measured in young adults. This is not merely correlational: experimental depletion of NAD+ produces many features of aging at the cellular level, while restoration of NAD+ in aged animal models can partially reverse age-related functional decline.
NAD+ is not a peptide, protein, or hormone in the conventional sense — it is a small molecule dinucleotide that serves simultaneously as a classical coenzyme for oxidoreductases and as the obligate substrate for a family of NAD+-consuming signaling enzymes. This dual role — as an electron carrier in metabolism and as a consumed substrate in signaling — means that NAD+ availability is both a measure of cellular energy status and a rate-limiting constraint on cellular repair, gene regulation, and stress response capacity.
NAD+ Biosynthesis — How Cells Make and Recycle NAD+
Understanding NAD+ supplementation requires understanding how cells maintain NAD+ homeostasis through biosynthetic and salvage pathways.
De novo synthesis from tryptophan: The kynurenine pathway converts tryptophan through a series of enzymatic steps to quinolinic acid, which is converted to nicotinic acid mononucleotide (NAMN), and ultimately to NAD+ through the Preiss-Handler pathway. This is the de novo route from dietary protein.
Preiss-Handler pathway from niacin: Dietary nicotinic acid (niacin, vitamin B3) is converted to NAMN by nicotinic acid phosphoribosyltransferase, then to NAD+ through nicotinic acid mononucleotide adenylyltransferase and NAD synthetase.
Salvage pathway from nicotinamide — the predominant intracellular route: The salvage pathway is the primary means by which cells regenerate NAD+ from the nicotinamide released when NAD+ is consumed by sirtuins, PARPs, and CD38. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme that converts nicotinamide to NMN, which is then converted to NAD+ by NMN adenylyltransferases (NMNATs). NAMPT expression and activity are critical determinants of intracellular NAD+ levels.
NR and NMN supplementation routes: Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors that feed into the salvage pathway — NR through NR kinases (NRK1/2), and NMN through NMNAT enzymes. These are the most actively studied NAD+ precursors in current clinical research because they can raise intracellular NAD+ levels without requiring de novo synthesis.
Direct NAD+ supplementation: Exogenous NAD+ itself has different pharmacokinetics from precursors — circulating NAD+ is rapidly hydrolyzed by CD38 and other ecto-enzymes on cell surfaces, and the intact NAD+ molecule has limited ability to cross intact cell membranes. Precursors are therefore generally considered more effective for raising intracellular NAD+ than direct NAD+ supplementation, though intravenous NAD+ has been used clinically in certain contexts and can rapidly raise plasma NAD+ levels.
Why NAD+ Levels Decline With Aging
The age-related decline in NAD+ is driven by multiple converging mechanisms:
Increased NAD+ consumption: The primary NAD+-consuming enzymes — PARPs (activated by DNA damage), CD38 (expressed on immune cells and increasingly activated with age-associated inflammation), and sirtuins (which require NAD+ for deacetylase activity) — all show increased or altered activity with aging. Accumulated DNA damage from decades of oxidative stress and UV exposure chronically activates PARP1, which consumes large quantities of NAD+ during DNA repair. Age-associated chronic inflammation drives CD38 upregulation on macrophages and other immune cells, consuming NAD+ in inflammatory signaling cascades. This competition for NAD+ among multiple high-affinity consuming enzymes depletes the available pool faster than it can be replenished.
Reduced biosynthetic capacity: NAMPT expression — the rate-limiting enzyme in the salvage pathway — declines with age in multiple tissues. This reduced capacity to salvage nicotinamide and convert it back to NMN and NAD+ compounds the consumption problem.
Reduced substrate availability: Dietary intake of NAD+ precursors may be insufficient relative to increased demand in aged tissues.
Compartmentalization changes: The distribution of NAD+ between mitochondrial, cytoplasmic, and nuclear pools changes with age, potentially creating compartment-specific deficits even when total cellular NAD+ appears only modestly reduced.
Mechanism of Action — The Four NAD+-Dependent Systems
NAD+ functions in four mechanistically distinct biological contexts that together explain its broad relevance to health and aging.
Redox coenzyme for energy metabolism: In its classical biochemical role, NAD+ is reduced to NADH by accepting hydride ions (H-) in oxidative metabolic reactions. In glycolysis, NAD+ accepts electrons from glyceraldehyde-3-phosphate, generating NADH and enabling continued glucose catabolism. In the TCA cycle, multiple dehydrogenase reactions reduce NAD+ to NADH, which then donates electrons to Complex I of the mitochondrial electron transport chain, driving the electrochemical gradient that powers ATP synthase. Without sufficient NAD+, these fundamental energy-generating reactions slow. The NAD+/NADH ratio is a direct measure of cellular redox and metabolic state.
Sirtuin (SIRT1-7) cofactor: Sirtuins are NAD+-dependent deacetylases and deacylases that remove acetyl and acyl groups from lysine residues of histones and other proteins, consuming NAD+ in the process and releasing nicotinamide. SIRT1 deacetylates histones (influencing gene expression) and transcription factors including PGC-1alpha (driving mitochondrial biogenesis), p53 (modulating DNA damage response), FOXO transcription factors (regulating stress resistance and longevity), and NF-kB (suppressing inflammation). SIRT3 maintains mitochondrial protein acetylation homeostasis and protects mitochondria from oxidative stress. Other sirtuins regulate diverse processes from telomere maintenance (SIRT6) to mitochondrial gene expression (SIRT7). Because sirtuins require NAD+ as an obligate substrate — not merely a cofactor — their activity is directly rate-limited by NAD+ availability. Age-related NAD+ decline suppresses sirtuin activity, contributing to the epigenetic dysregulation, metabolic dysfunction, and reduced stress resilience of aging.
PARP (poly-ADP-ribose polymerase) substrate for DNA repair: PARP1 is the primary nuclear enzyme activated by DNA strand breaks and other DNA damage. PARP1 uses NAD+ as a substrate to generate poly-ADP-ribose (PAR) chains on itself and other proteins at sites of DNA damage, recruiting DNA repair machinery. Each PAR synthesis event consumes one NAD+ molecule; extensive DNA damage can trigger massive PARP1 activation that depletes cellular NAD+ by up to 80%, causing metabolic crisis through energy depletion rather than through direct DNA damage. Chronically elevated DNA damage in aged tissues chronically activates PARP1, contributing to the age-related NAD+ decline. Maintaining adequate NAD+ levels ensures sufficient substrate for DNA repair while also preserving sirtuin activity, which additionally modulates DNA damage response.
CD38 and cyclic ADP-ribose calcium signaling: CD38 is an ecto-enzyme expressed on the surface of immune cells, neurons, and other cell types. It hydrolyzes NAD+ to produce cyclic ADP-ribose (cADPR), a potent intracellular calcium-mobilizing messenger, and ADPR. CD38 expression increases with aging and inflammation — it is upregulated in macrophages during inflammaging — making it a major contributor to age-related NAD+ depletion. CD38-produced cADPR mediates calcium signaling important for immune function and neuronal activity.
Published Research
Study 1 — Landmark Review: NAD+ in Aging, Metabolism, and Neurodegeneration (Science)
Authors: Verdin E (Gladstone Institutes, UCSF) Year: 2015 Journal: Science Referenced via: Science. 2015;350(6265):1208-13
This landmark Science perspective by Eric Verdin synthesized the evidence for NAD+’s expanded biological roles beyond redox metabolism, establishing the conceptual framework that has organized NAD+ aging research for the subsequent decade.
NAD+ serves as a cosubstrate for sirtuins, PARPs, CD38/157 ectoenzymes, and other signaling proteins in which it is consumed with concomitant release of nicotinamide — distinguishing these enzymatic reactions from the redox cycle where NAD+ is regenerated.
The NAD+ salvage pathway through NAMPT is the primary mechanism by which cells regenerate NAD+ from nicotinamide, and NAMPT expression and activity are key rate-limiting determinants of sirtuin activity and DNA repair capacity.
NAD+ levels decline with aging across multiple tissues, and this decline is causally linked to reduced sirtuin activity, impaired DNA repair, mitochondrial dysfunction, and the metabolic dysregulation characteristic of aging.
The paper directly connected NAD+ decline to major hallmarks of aging including epigenetic dysregulation (through sirtuin activity loss), mitochondrial dysfunction (through sirtuin/PGC-1alpha axis suppression), genomic instability (through PARP/sirtuin competition for NAD+), and altered intercellular communication.
Study 2 — Human Tissue Evidence: Age-Associated Changes in NAD+ and SIRT1 in Human Skin
Authors: Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ Year: 2012 Journal: PLOS ONE PMID: 22848760 Full text: https://pubmed.ncbi.nlm.nih.gov/22848760/
This was among the first studies to directly measure NAD+ levels, PARP activity, and SIRT1 activity in human tissue samples across a broad age range — providing the human tissue evidence for the age-associated NAD+ decline.
Human pelvic skin samples from 49 patients aged 0 to 77 years confirmed that DNA damage (measured by gamma-H2AX) correlated strongly with age in males (P equal to 0.029, r equal to 0.490) and females (P equal to 0.003, r equal to 0.600).
PARP activity increased with age in males, consistent with PARP1 activation by the increasing DNA damage burden. In post-pubescent males, PARP activity was negatively correlated with NAD+ levels (P equal to 0.0149) — directly demonstrating the competitive consumption relationship between PARP and NAD+ availability in human tissue.
SIRT1 activity declined significantly with age in post-pubescent males (P equal to 0.007, r equal to -0.612) — confirming that the predicted link between NAD+ decline and sirtuin activity loss is present in human tissue, not only in animal models.
These findings directly established in human tissue the mechanistic sequence: increasing DNA damage with age → PARP1 hyperactivation → NAD+ depletion → SIRT1 suppression — a causal chain that connects aging-associated DNA damage accumulation to the broader metabolic and epigenetic dysfunction of aging.
Study 3 — Comprehensive Review: NAD+ in Aging Biology — Potential Applications and Many Unknowns (Endocrine Reviews)
Authors: Bhasin S, Seals D, Migaud M, Musi N, Baur JA (Harvard, University of Colorado, University of Southern Alabama, Cedars-Sinai, University of Pennsylvania) Year: 2023 Journal: Endocrine Reviews PMID: 37364580 Full text: https://pubmed.ncbi.nlm.nih.gov/37364580/
This 2023 comprehensive review in Endocrine Reviews synthesized the complete evidence base for NAD+ biology in aging — covering biosynthetic pathways, consuming enzyme families, age-related decline mechanisms, and the clinical trial landscape for NAD+ precursor supplementation.
NAD+ plays important roles in energy generation, redox reactions, and as a substrate or cosubstrate in signaling pathways that regulate healthspan and aging — with the latter role involving the irrecoverable consumption of NAD+ during sirtuin, PARP, CD38, and SARM1 reactions.
NADH (the reduced form) is stable to the glycosidic bond cleavage that would release nicotinamide and serves as a protected pool of NAD+ — available for regeneration by Complex I of the ETC and lactate dehydrogenase, but not directly available for sirtuin or PARP reactions.
The review characterized the current clinical trial landscape for NAD+ precursor supplementation in aging, noting that while preclinical evidence strongly supports NAD+ restoration as a strategy for healthy aging, clinical evidence in humans remains limited, mixed, and primarily drawn from short-duration trials with biomarker endpoints rather than hard clinical outcomes.
The review also identified key unknowns: tissue-specific differences in NAD+ decline and response to supplementation, optimal delivery routes and doses, long-term safety of sustained NAD+ elevation, and interaction between NAD+ levels and cancer risk given that many tumors have elevated NAD+ dependency.
Study 4 — Phase 1 Clinical Trial: Nicotinamide Riboside Supplementation in Parkinson’s Disease (NADPARK Study)
Authors: Brakedal B, Dölle C, Riemer F et al. (Haukeland University Hospital, Bergen; Feinstein Institutes) Year: 2022 Journal: Cell Metabolism PMID: 35235774 Full text: https://www.sciencedirect.com/science/article/pii/S1550413122000456
The NADPARK study was the first randomized controlled trial to assess whether oral NAD+ precursor supplementation (nicotinamide riboside) could raise cerebral NAD+ levels and produce measurable neurological effects in Parkinson’s disease patients — using brain MR spectroscopy and FDG-PET to provide direct in vivo evidence of CNS NAD+ changes.
30 newly diagnosed, treatment-naive Parkinson’s disease patients were randomized to receive 1,000 mg NR daily or placebo for 30 days.
NR treatment was well tolerated and led to a significant but variable increase in cerebral NAD+ levels measured by 31-phosphorous magnetic resonance spectroscopy. Related NAD+ metabolites also increased in cerebrospinal fluid — confirming that oral NR can raise brain and CSF NAD+ in humans.
Participants with increased brain NAD+ levels exhibited altered cerebral metabolism measured by 18FDG-PET, consistent with improved bioenergetic efficiency, and this was associated with mild clinical improvement in MDS-UPDRS scores in those with NAD+ increases greater than 10%.
NR augmented the NAD metabolome and induced transcriptional upregulation of processes related to mitochondrial function, lysosomal function, and proteasomal function in blood cells and skeletal muscle — multiple dimensions of cellular health simultaneously improved.
NR decreased levels of inflammatory cytokines in serum and cerebrospinal fluid — providing evidence for anti-neuroinflammatory effects alongside the metabolic changes.
The authors concluded that their findings nominate NR as a potential neuroprotective therapy for Parkinson’s disease, warranting further investigation in larger trials.
Study 5 — Systematic Review: Safety and Effectiveness of NAD in Clinical Conditions
Authors: de Mello Gindri I et al. (University of Santa Catarina, Brazil) Year: 2024 Journal: American Journal of Physiology — Endocrinology and Metabolism PMID: 37971292 Full text: https://journals.physiology.org/doi/full/10.1152/ajpendo.00242.2023
This systematic review of randomized clinical trials examined the safety and effectiveness of NAD+ and NADH supplementation across multiple human clinical conditions, providing the most comprehensive synthesis of the controlled human trial evidence base available.
10 randomized clinical trials totaling 489 participants were included, spanning chronic fatigue syndrome, older adults, Parkinson’s disease, overweight/obesity, postmenopausal prediabetes, and Alzheimer’s disease.
NAD+ and NADH supplementation was well tolerated across all included trials, with no serious safety signals identified.
Across studies, supplementation produced documented benefits including decreased anxiety and reduced maximum heart rate during stress testing, increased muscle insulin sensitivity, improved insulin signaling, and mild improvements in cognitive measures in Alzheimer’s disease subjects.
For Parkinson’s disease, intravenous and intramuscular NADH administration produced improvements in Unified Parkinson’s Disease Rating Scale scores in the Dizdar et al. study — one of the earlier direct NADH administration studies referenced in this review.
The review concluded that supplementation with NADH and precursors is well tolerated and produces measurable clinical results across a range of conditions, while noting that the evidence base remains limited by small sample sizes, short durations, and heterogeneous study designs.
Study 6 — High-Dose Safety: NR-SAFE Parkinson’s Trial (Nature Communications)
Authors: Berven H, Kverneng S, Sheard E et al. (Haukeland University Hospital) Year: 2023 Journal: Nature Communications Full text: https://www.nature.com/articles/s41467-023-43514-6
This Phase 1 randomized double-blind placebo-controlled safety trial examined the highest doses of NR (3,000 mg daily) yet tested in humans — directly addressing the critical safety question of upper dose limits for NAD+ precursor supplementation.
20 Parkinson’s disease patients were randomized 1:1 to receive NR 1,500 mg twice daily (total 3,000 mg/day) or placebo for 4 weeks.
Oral NR at 3,000 mg daily for 30 days was safe, with no moderate or severe adverse events attributable to treatment — establishing that even very high doses of NR are safely tolerated in human subjects.
The 3,000 mg dose was associated with a pronounced systemic augmentation of the NAD metabolome — substantially larger increases in NAD+ and metabolites than in the 1,000 mg NADPARK trial.
Importantly, the high-dose NR did not produce methyl donor depletion — addressing a theoretical safety concern that nicotinamide-derived NAD+ precursors might deplete S-adenosylmethionine and impair methylation reactions.
The trial established that doses up to 3,000 mg NR daily represent a safe upper limit in the near term for clinical NAD+ augmentation research, enabling more aggressive dosing in larger efficacy trials.
NAD+ Supplementation: The Research Landscape and Key Distinctions
The current research landscape for NAD+ supplementation involves several overlapping but distinct strategies, each with different pharmacokinetic and biological profiles.
Direct NAD+: Exogenously administered NAD+ can raise plasma NAD+ levels rapidly, particularly through intravenous administration. However, NAD+ is hydrolyzed by CD38 and other ecto-enzymes before cellular uptake, and intact NAD+ has limited membrane permeability. Intravenous NAD+ produces a rapid spike in plasma NAD+ that is primarily converted to precursors before cellular uptake. Buffered formulations are used to improve tolerability. Published pilot data on intravenous NAD+ infusion documented a 398% increase in plasma NAD+ accompanied by a small but significant rise in bilirubin, suggesting possible red blood cell turnover at infusion.
NR (nicotinamide riboside): The most extensively studied precursor in human clinical trials. Enters cells through nucleoside transporters, is phosphorylated to NMN by NR kinases, and then converted to NAD+ by NMNATs. Multiple human RCTs have confirmed NR raises blood, muscle, and CSF NAD+ levels at doses of 500-3,000 mg/day. NR does not produce the flushing that limits niacin use.
NMN (nicotinamide mononucleotide): Directly converted to NAD+ by NMNAT enzymes. More recent clinical trial data shows NMN raises blood NAD+ levels in humans. Multiple Phase 1 and 2 trials are ongoing.
Niacin (nicotinic acid): The oldest NAD+ precursor therapy, used clinically for decades primarily for dyslipidemia. Strongly raises NAD+ but produces prostaglandin-mediated cutaneous flushing that limits dose and patient acceptability. Some evidence for neuroprotective and mitochondrial effects at tolerable doses.
Nicotinamide (NAM): Inexpensive and bioavailable but at high doses inhibits SIRT1 and PARP activity by product inhibition (nicotinamide is the cleavage product of NAD+ in sirtuin and PARP reactions), potentially counteracting some of the sirtuin-mediated benefits of NAD+ restoration.
An Honest Assessment of the Human Evidence Base
The preclinical evidence for NAD+ restoration as an anti-aging intervention is among the most compelling in the entire longevity research field — dozens of well-controlled animal studies demonstrating reversal of age-related dysfunction, metabolic improvement, and extended lifespan through NAD+ precursor supplementation. The mechanistic rationale is well-grounded in understood biochemistry.
The human clinical evidence is more limited and mixed. Most completed human trials are short-duration (4-12 weeks), small-sample (10-50 subjects), and powered for biomarker endpoints (blood NAD+ levels, inflammatory markers) rather than hard clinical outcomes (reduced disease incidence, improved functional capacity at follow-up, mortality). Results across trials are generally positive for safety and biomarker evidence of NAD+ elevation, but effects on clinical outcomes are modest and inconsistent across studies. The Endocrine Reviews 2023 consensus review characterized the current state as having established that NAD+ levels can be raised safely in humans through precursor supplementation, while noting that evidence of meaningful clinical benefit from this elevation remains to be established in appropriately powered long-term trials.
Current Research Status
NAD+ and its precursors are not FDA-approved for any specific therapeutic indication. Active research directions include Parkinson’s disease neuroprotection (Phase 2 trials underway following NADPARK), Alzheimer’s disease and cognitive aging, muscle function and sarcopenia, metabolic disease including insulin resistance and type 2 diabetes, cardiovascular aging, and healthy aging biomarker studies. Multiple academic centers and biotechnology companies have active clinical development programs. NAD+ precursors (particularly NR and NMN) are available as dietary supplements in the United States without specific disease indication claims.
Reconstitution Note (Buffered NAD+)
Buffered NAD+ is supplied as a lyophilized powder adjusted to near-physiological pH to reduce injection site discomfort. Reconstitute with sterile water or bacteriostatic water per the specific lot datasheet. Use the volume specified to achieve the intended concentration — do not over-dilute, as pH buffering depends on appropriate concentration. Buffered NAD+ solutions should be used promptly after reconstitution. Protect from light. Always confirm the recommended solvent and reconstitution volume against the specific lot datasheet before use.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted NAD+ solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages. NAD+ in solution is subject to hydrolysis — use within the timeframe recommended for the specific lot. Do not store for extended periods after reconstitution. Discard any solution showing visible discoloration, turbidity, or particulates.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the NAD+ (Buffered) product page: https://roguecompounds.com/product/nad/